Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion

Journal of Viral Hepatitis

Volumn 9, Issue 3, 2002, Pages 208-212

  Lee, K M ^a   Cho, Sung Won ^a   Kim, S W ^a   Kim, H J ^a   Hahm, K B ^a   Kim, J H ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

HBeAg seroconversion; Lamivudine; Relapse; Ultrasensitive HBV DNA assay

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; SEROCONVERSION; TREATMENT OUTCOME; VIROLOGY; VIRUS GENOME;

ANTIVIRAL AGENTS; DNA, VIRAL; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; REAGENT KITS, DIAGNOSTIC; RECURRENCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SENSITIVITY AND SPECIFICITY;

EID: 0036906811     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2002.00357.x     Document Type: Article

References (21)

1. Doong ST, Tsai CH, Schimazi RF et al. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogue. Proc Natl Acad Sci USA 1991; 88: 8495-8499.
2. Chang CN, Skalski V, Zhou JH et al. Biochemical pharmacology of (+) and (-) 2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J Biol Chem 1992; 267: 22414-22420.
3. Lai CL, Chien RN, Leung NWY et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-68.
4. Cho SW, Hahm KB, Kim JH. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology 2000; 32: 1172-1174.
5. Boni C, Bertoletti A, Penna A et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968-975.
6. Dienstag JL, Schiff ER, Mitchell M et al. Extended lamivudine retreatment for chronic hepatitis B. maintenance of viral suppression after discontinuation of therapy. Hepatology 1999; 30: 1082-1087.
7. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-1263.
8. Hoofnagle JH, Peters M, Mullen KD et al. Randomized controlled trials of recombinant human α-interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95: 1318-1325.
9. Koreman J, Baker B, Waggoner J et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Int Med 1991; 114: 629-634.
10. Honkoop P, de Man RA, Niesters HGM et al. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32: 635-639.
11. Song BC, Suh DJ, Lee HC et al. Hepatitis B e antigen sero-conversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 803-806.
12. Honkoop P, Niesters HGM, de Man RA et al. Lamivudine resistance in immunocompetent chronic hepatitis B. J Hepatol 1997; 26: 1393-1395.
13. Gauthier J, Bourne EJ, Lutz MW et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 1999; 180: 1757-1762.
14. Nevens F, Honkoop P, Tyrrell DL et al. Lamivudine therapy for chronic hepatitis B: A six months randomized dose-ranging study. Gastroenterology 1997; 113: 1258-1263.
15. Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and alpha interferone combination treatment of patients with chronic hepatitis B infection: A randomized trial. Gut 2000; 46: 562-568.
16. Chien RN, Liaw YF, Atkins M for the Asian Hepatitis Lamivudine Trial Group. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999; 30: 770-774.
17. Lok ASF, Lai CL, Wu PC et al. Long-term follow-up in a randomized controlled trial of recombinant α2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988; 2: 298-302.
18. Davis GL, Hoofnagle JH, Waggoner JG et al. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology 1984; 86: 230-235.
19. Moraleda G, Saputelli J, Aldrich CE et al. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997; 71: 9392-9399.
20. Mason WS, Cullen J, Saputelli J et al. Characterization of the antiviral effects of 2′-carbodeoxyguanosine in ducks chronically infected with duck hepatitis B virus. Hepatology 1994; 19: 398-341.
21. Pichoud C, Berby F, Stuyver L et al. Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B. J Hepatol 2000; 32: 307-316.